Hormone Replacement Therapy for Perimenopausal Women

Introduction to Hormone Replacement Therapy

The American College of Obstetricians and Gynecologists recommends that perimenopausal women experiencing bothersome vasomotor or genitourinary symptoms can initiate hormone replacement therapy without waiting for complete cessation of menses, using transdermal estradiol 50 μg twice weekly plus micronized progesterone 200 mg nightly for those with an intact uterus 1

Perimenopausal women can initiate hormone replacement therapy when symptoms begin, with no requirement to delay until after the final menstrual period, as stated by the North American Menopause Society 1
The most favorable benefit-risk profile exists for women under 60 years of age or within 10 years of menopause onset, which includes perimenopausal women, according to the American College of Obstetricians and Gynecologists 1
Ovarian estrogen and progestin production begins declining years before complete cessation of menses, and symptoms can be treated as they emerge, as noted by the American Academy of Family Physicians 2

For women with an intact uterus, the recommended regimen is transdermal estradiol patches 50 μg daily (changed twice weekly) PLUS micronized progesterone 200 mg orally at bedtime, as recommended by the American College of Obstetricians and Gynecologists 1
The progestin component is mandatory to prevent endometrial hyperplasia and cancer, reducing risk by approximately 90%, according to the National Institute of Health 1
Transdermal delivery is preferred over oral formulations because it bypasses hepatic first-pass metabolism, resulting in lower cardiovascular and thromboembolic risks, as stated by the Endocrine Society 1

For every 10,000 women taking combined estrogen-progestin therapy for 1 year, there are 8 additional invasive breast cancers, 8 additional strokes, 8 additional pulmonary emboli, 7 additional coronary heart disease events, 6 fewer colorectal cancers, and 5 fewer hip fractures, as reported by the American Heart Association 2

Reassess symptom control and necessity for continuation every 3-6 months, and plan to attempt discontinuation or dose reduction after symptoms stabilize, typically aiming for treatment duration under 5 years when possible, as recommended by the American College of Obstetricians and Gynecologists 2
Continue mammography screening per standard guidelines, as stated by the American Cancer Society 1

If only vaginal dryness/atrophy is present without vasomotor symptoms, use low-dose vaginal estrogen preparations (rings, suppositories, or creams) without systemic progestin, as recommended by the North American Menopause Society 1
These improve genitourinary symptoms by 60-80% with minimal systemic absorption, according to the American College of Obstetricians and Gynecologists 1